New drug treatment and mechanism of action of the central anticholinergic drug trihexylphenidyl in reducung posttraumatic nightmares and Fiashbacks in patients with posttraumtic stress disoder,and the occurrence hyposthesis of nightmares and flashbacks.

New drug treatment and mechanism of action of the central anticholinergic drug trihexylphenidyl in reducung posttraumatic nightmares and Fiashbacks in patients with posttraumtic stress disoder,and the occurrence hyposthesis of nightmares and flashbacks. - the new drug treatment:cehtral anticgolinergic drug Truhexylphenidyl in posttraumatic nightmares and the drug effect mechanism.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028461

Enrollment

Registered

2017-07-31

Start date

2018-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posttraumatic stress disorder.

Interventions

Using the cehtral anticholinergic agent Trihexylphenidyl for posttraumatic nightmares and observe therapeutic effect.Trihexylphenidyl2mg1T~2T is administered before bedtime.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Originally PTSD may nave refractory elements, but at the time of first visit our clinic, patients with intractable PTSD who already received various treatments at various medical institutions were targeted.

Exclusion criteria

Exclusion criteria: Men and women aged under 20 and over 40 years old, pregnant women, lactating women were excluded.

Design outcomes

Primary

Measure	Time frame
Central anticholinergic drug:Trihexylphenidyl (an existing drug was used from 65 years ago)administered to refractory PTSD-patients with posttraumaic nightmares. Respond to symptom to refractory PTSD who came in 2009~2017,Trihexylphenidyl 2mg/1T~3T was administered.It was evaluated by CAPS(Clinical Administered PTSD Scale) and IES-R( the Impact of Event Scale-Revised). Clinical evalluation is suprising to say that Complete Remission:70.3%+Partial Remission:29.7%=almost 100%. Moreover, this medicine is fast-acting, certainty, drug mechanism clear.	—

Measure

Time frame

Central anticholinergic drug:Trihexylphenidyl (an existing drug was used from 65 years ago)administered to refractory PTSD-patients with posttraumaic nightmares. Respond to symptom to refractory PTSD who came in 2009~2017,Trihexylphenidyl 2mg/1T~3T was administered.It was evaluated by CAPS(Clinical Administered PTSD Scale) and IES-R( the Impact of Event Scale-Revised). Clinical evalluation is suprising to say that Complete Remission:70.3%+Partial Remission:29.7%=almost 100%. Moreover, this medicine is fast-acting, certainty, drug mechanism clear.

—

Secondary

Measure	Time frame
I found the following onset hypothesis from this research. The hypothesis of flashbacks has a deep relationship with the brain ACh basal ganglia(Ch1,Ch2,Ch4) and amygdala,hippocampus. The hypothesis of posttraumatic nightmares has a deep relationship with hypothesis of flashbacks and Ch5,Ch6 of the brain stem which is said to occur regular REM.	—

Countries

Japan

Contacts

Public ContactKatsumasa Sogo

Medical Corporation Sogo-kai Sogo-Clinic sogo ptsd institute

sogoutiger@nifty.com082-261-0280

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026